A new systematic review and meta-analysis published in the Clinical Nutrition ESPEN revealed promising outcomes for the ...

Ozempic is traditionally used as a treatment for type 2 diabetes (T2DM) to help patients manage blood sugar levels. However, ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Experts are calling on the government to implement strategies that will better predict future Ozempic shortages.

Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Physician–scientists at the University of Utah's John A. Moran Eye Center have published an investigatory review of nine patients who experienced vision complications while taking popular semaglutide ...

Telehealth company Him & Hers Health is taking a very different approach to its Super Bowl ad this year - as its new ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to a new study.

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Online pharmacies in England, Wales, and Scotland will have to carry out stricter checks on people who are buying weight loss drugs, under new regulatory guidance. Pharmacists will no longer be able ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...